Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
141.65
-0.64 (-0.45%)
At close: May 20, 2024, 4:00 PM
141.00
-0.65 (-0.46%)
After-hours: May 20, 2024, 7:53 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for NBIX stock have an average target of 150.18, with a low estimate of 100 and a high estimate of 216. The average target predicts an increase of 6.02% from the current stock price of 141.65.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NBIX stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 9 | 9 | 9 | 8 | 9 | 10 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 21 | 22 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $175 | Buy | Initiates | $175 | +23.54% | May 14, 2024 |
| Citigroup | Citigroup | Hold Maintains $140 → $150 | Hold | Maintains | $140 → $150 | +5.89% | May 3, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $154 → $164 | Strong Buy | Maintains | $154 → $164 | +15.78% | May 2, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $164 → $170 | Strong Buy | Maintains | $164 → $170 | +20.01% | May 2, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $169 | Buy | Maintains | $150 → $169 | +19.31% | May 2, 2024 |
Financial Forecast
Revenue This Year
2.26B
from 1.89B
Increased by 19.71%
Revenue Next Year
2.63B
from 2.26B
Increased by 16.25%
EPS This Year
4.87
from 2.47
Increased by 97.14%
EPS Next Year
6.44
from 4.87
Increased by 32.26%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.4B | 4.0B | 3.8B | 4.6B | 5.4B |
| Avg | 2.3B | 2.6B | 3.0B | 3.4B | 3.9B |
| Low | 2.1B | 2.2B | 2.3B | 2.9B | 3.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.1% | 75.7% | 43.8% | 53.9% | 57.0% |
| Avg | 19.7% | 16.2% | 12.9% | 15.4% | 13.5% |
| Low | 11.1% | -1.9% | -10.9% | -3.6% | -11.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.01 | 8.94 | 11.94 | 16.85 | 19.67 |
| Avg | 4.87 | 6.44 | 8.65 | 12.24 | 14.29 |
| Low | 3.76 | 4.49 | 6.04 | 8.72 | 10.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 143.2% | 83.5% | 85.4% | 94.8% | 60.7% |
| Avg | 97.1% | 32.3% | 34.3% | 41.5% | 16.8% |
| Low | 52.4% | -7.8% | -6.3% | 0.8% | -18.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.